ADMA Biologics (NASDAQ:ADMA) Price Target Raised to $15.00

ADMA Biologics (NASDAQ:ADMA) had its target price raised by Cantor Fitzgerald from $10.00 to $15.00 in a research report released on Tuesday, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

A number of other analysts have also issued reports on ADMA. HC Wainwright boosted their price target on shares of ADMA Biologics from $7.50 to $10.00 and gave the stock a buy rating in a research note on Friday, May 10th. Mizuho boosted their price target on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a buy rating in a research note on Thursday, June 20th. Finally, Raymond James boosted their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the stock a strong-buy rating in a research note on Friday, May 10th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Buy and a consensus price target of $12.25.

ADMA Biologics Stock Up 2.6 %

Shares of ADMA opened at $12.31 on Tuesday. The firm has a market cap of $2.85 billion, a P/E ratio of -615.50 and a beta of 0.55. ADMA Biologics has a 12-month low of $3.06 and a 12-month high of $12.47. The company’s 50-day moving average price is $10.03 and its 200 day moving average price is $7.16. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.03. The firm had revenue of $81.90 million for the quarter, compared to analyst estimates of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. ADMA Biologics’s revenue was up 43.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.03) EPS. On average, sell-side analysts forecast that ADMA Biologics will post 0.35 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Adam S. Grossman sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the sale, the chief executive officer now directly owns 2,081,475 shares in the company, valued at $22,313,412. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in ADMA Biologics by 2.7% in the third quarter. Vanguard Group Inc. now owns 12,781,695 shares of the biotechnology company’s stock valued at $45,758,000 after purchasing an additional 336,190 shares in the last quarter. Stonepine Capital Management LLC boosted its holdings in ADMA Biologics by 1.3% in the fourth quarter. Stonepine Capital Management LLC now owns 9,222,617 shares of the biotechnology company’s stock valued at $41,686,000 after purchasing an additional 118,342 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of ADMA Biologics by 20.8% in the third quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock valued at $17,514,000 after acquiring an additional 840,761 shares during the period. Mesirow Institutional Investment Management Inc. acquired a new stake in shares of ADMA Biologics in the first quarter valued at approximately $17,221,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of ADMA Biologics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,636,703 shares of the biotechnology company’s stock valued at $7,398,000 after acquiring an additional 27,357 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.